EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mitochondrial Fraction of Circulating Cell-Free DNA as an Indicator of Human Pathology

Maria Panagopoulou iD, Makrina Karaglani, Konstantina Tzitzikou iD, Nikoleta Kessari, Konstantinos Arvanitidis iD, Kyriakos Amarantidis, George I Drosos, Spyros Gerou, Nikolaos Papanas iD, Dimitrios Papazoglou iD, Stavroula Baritaki iD, Theodoros C Constantinidis iD und 1 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25084199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Maria Panagopoulou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacology, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, DNA, Mitochondrial, Diabetes Mellitus, Type 2, Breast Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE, Hellenic Foundation for Research and Innovation, European Regional Development Fund of the European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating cell-free DNA (ccfDNA) of mitochondrial origin (ccf-mtDNA) consists of a minor fraction of total ccfDNA in blood or in other biological fluids. Aberrant levels of ccf-mtDNA have been observed in many pathologies. Here, we introduce a simple and effective standardized Taqman probe-based dual-qPCR assay for the simultaneous detection and relative quantification of nuclear and mitochondrial fragments of ccfDNA. Three pathologies of major burden, one malignancy (Breast Cancer, BrCa), one inflammatory (Osteoarthritis, OA) and one metabolic (Type 2 Diabetes, T2D), were studied. Higher levels of ccf-mtDNA were detected both in BrCa and T2D in relation to health, but not in OA. In BrCa, hormonal receptor status was associated with ccf-mtDNA levels. Machine learning analysis of ccf-mtDNA datasets was used to build biosignatures of clinical relevance. (A) a three-feature biosignature discriminating between health and BrCa (AUC: 0.887) and a five-feature biosignature for predicting the overall survival of BrCa patients (Concordance Index: 0.756). (B) a five-feature biosignature stratifying among T2D, prediabetes and health (AUC: 0.772); a five-feature biosignature discriminating between T2D and health (AUC: 0.797); and a four-feature biosignature identifying prediabetes from health (AUC: 0.795). (C) a biosignature including total plasma ccfDNA with very high performance in discriminating OA from health (AUC: 0.934). Aberrant ccf-mtDNA levels could have diagnostic/prognostic potential in BrCa and Diabetes, while the developed multiparameter biosignatures can add value to their clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell-Free Nucleic AcidsDNA, MitochondrialDiabetes Mellitus, Type 2Breast NeoplasmsHumansFemaleMitochondriaMiddle AgedMaleAgedMachine Learning

Stichwörter der Autor:innen

breast cancerccfDNAdiabetesmachine learningmitochondrialosteoarthritisprediabetes

Substanzen

Cell-Free Nucleic AcidsDNA, Mitochondrial

Autor:innen und Institutionen

  • Laboratory of Pharmacology, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
  • Institute of Agri-Food and Life Sciences, University Research and Innovation Centre, Hellenic Mediterranean University, 71003 Heraklion, Greece.
  • Clinic of Medical Oncology, Department of Medicine, Democritus University of Thrace, University General Hospital of Alexandroupolis, 68100 Alexandroupolis, Greece.
  • Clinic of Orthopaedic Surgery, Department of Medicine, Democritus University of Thrace, University General Hospital of Alexandroupolis, 68100 Alexandroupolis, Greece.
  • Analysis Biopathological Diagnostic Research Laboratories, 54623 Thessaloniki, Greece.
  • Diabetes Centre, 2nd Department of Internal Medicine, University Hospital of Alexandroupolis, 68100 Alexandroupolis, Greece.

ORCID-Profile: Maria Panagopoulou, Konstantina Tzitzikou, Konstantinos Arvanitidis, Nikolaos Papanas, Dimitrios Papazoglou, Stavroula Baritaki, Theodoros C Constantinidis, Ekaterini Chatzaki

Förderung

  • Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE
  • Hellenic Foundation for Research and Innovation
  • European Regional Development Fund of the European Union

Zitieren

APA

Panagopoulou, M., Karaglani, M., Tzitzikou, K., Kessari, N., Arvanitidis, K., Amarantidis, K., Drosos, G. I., Gerou, S., Papanas, N., Papazoglou, D., Baritaki, S., Constantinidis, T. C., & Chatzaki, E. (2024). Mitochondrial Fraction of Circulating Cell-Free DNA as an Indicator of Human Pathology. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084199

Vancouver

Panagopoulou M, Karaglani M, Tzitzikou K, Kessari N, Arvanitidis K, Amarantidis K, et al. Mitochondrial Fraction of Circulating Cell-Free DNA as an Indicator of Human Pathology. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25084199

BibTeX
@article{Panagopoulou2024,
  author = {Panagopoulou, Maria and Karaglani, Makrina and Tzitzikou, Konstantina and Kessari, Nikoleta and Arvanitidis, Konstantinos and Amarantidis, Kyriakos and Drosos, George I and Gerou, Spyros and Papanas, Nikolaos and Papazoglou, Dimitrios and Baritaki, Stavroula and Constantinidis, Theodoros C and Chatzaki, Ekaterini},
  title = {Mitochondrial Fraction of Circulating Cell-Free DNA as an Indicator of Human Pathology},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25084199}
}
Kostenlos starten →